Is Eli Lilly Stock a Buy?
Type 2 diabetes and obesity have become an increasing global healthcare problem, reaching near crisis proportions in the United States. The arrival of GLP-1 agonists, drugs that mimic hormones to slow digestion and quell hunger, offers a potential solution and has created one of the pharmaceutical industry's most lucrative opportunities in recent history.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales of GLP-1 agonists could grow at a 33% annualized rate, reaching $471 billion by 2032.
Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now.
Source Fool.com
